| P2093 | author name string | Neil Blumberg | |
| | Joanna Mary Heal | |
| P2860 | cites work | Thrombocytopenia in critically ill surgical patients: a case-control study evaluating attributable mortality and transfusion requirements | Q24794504 |
| | Aspirin and mortality from coronary bypass surgery | Q28194029 |
| | Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. | Q33334908 |
| | Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 |
| | Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions | Q33337118 |
| | Lowering the prophylactic platelet transfusion threshold: a prospective analysis | Q33337229 |
| | Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions | Q33340587 |
| | The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy | Q33343369 |
| | Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial | Q33345486 |
| | Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia | Q33346908 |
| | Guidelines for the use of platelet transfusions | Q33348675 |
| | Prophylactic platelet transfusions: which dose is the best dose? A review of the literature | Q33349172 |
| | Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia | Q33371869 |
| | Platelet Crossmatching: A Direct Approach to the Selection of Platelet Transfusions for the Alloimmunized Thrombocytopenic Patient | Q33451153 |
| | The Prophylactic Treatment of Thrombocytopenic Leukemic Patients with Platelets: a Double Blind Study | Q33465206 |
| | Circulating immune complexes involving the ABO system after platelet transfusion | Q72311527 |
| | A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions | Q72323530 |
| | Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates | Q72337786 |
| | The febrile platelet transfusion reaction: a cytokine shower | Q72418164 |
| | Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis | Q72524416 |
| | Cytokine generation in stored platelet concentrates | Q72686709 |
| | ABO and platelet transfusion revisited | Q72799054 |
| | Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components | Q72901080 |
| | Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL | Q73132195 |
| | Evaluation of donor skin disinfection methods | Q73277667 |
| | Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats | Q73336542 |
| | Central venous catheter placement in patients with disorders of hemostasis | Q73448382 |
| | International forum: granulocyte transfusions | Q73500316 |
| | The use of platelet concentrates versus plateletpheresis-the donor perspective | Q74001409 |
| | Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections | Q74418641 |
| | The relationship between the duration of platelet storage and the development of transfusion reactions | Q74489008 |
| | Clinical evaluation of transfusion of prestorage-leukoreduced apheresis platelets | Q77451469 |
| | Preparation of leukodepleted platelet concentrates from pooled buffy coats: prestorage filtration with Autostop BC | Q77962038 |
| | Transfusion-related acute lung injury | Q78057891 |
| | ABO-mismatched platelet transfusions and clinical outcomes after cardiac surgery | Q78487361 |
| | A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger | Q78523412 |
| | The causes and treatment of reactions to platelet transfusions | Q78859791 |
| | Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia | Q33475632 |
| | Indications for platelet transfusion in children with acute leukemia | Q33483256 |
| | The role of the plasma from platelet concentrates in transfusion reactions | Q33491828 |
| | Central venous catheter placement in patients with disorders of hemostasis | Q33496106 |
| | Patients with thrombocytopenia: outcome of radiologic placement of central venous access devices | Q33499674 |
| | The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. | Q33501152 |
| | Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions | Q33501221 |
| | Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation | Q33504600 |
| | Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective | Q33581221 |
| | Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program | Q33726826 |
| | Considerations in the selection of a platelet component: apheresis versus whole blood-derived | Q33769745 |
| | Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy | Q34306589 |
| | Bacterial contamination of platelet concentrates: incidence, significance, and prevention | Q34451446 |
| | The rationale for pathogen inactivation treatment of platelet components--introduction | Q34472497 |
| | Bacterial contamination of blood products: factors, options, and insights | Q34522392 |
| | Refractoriness to platelet transfusion | Q34977566 |
| | A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets | Q40579927 |
| | Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations | Q40628811 |
| | A prospective study of symptomatic bacteremia following platelet transfusion and of its management | Q40694155 |
| | A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions | Q40712333 |
| | Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions | Q40748675 |
| | Febrile reactions after platelet transfusion: the effect of single versus multiple donors | Q40764863 |
| | Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. | Q42996768 |
| | Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population | Q43040535 |
| | A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets | Q43479927 |
| | Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period | Q44170176 |
| | Central venous catheterization in patients with coagulopathy | Q44359073 |
| | HLA class II antibodies in transfusion-related acute lung injury. | Q45957230 |
| | WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization | Q47808025 |
| | Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity | Q48623928 |
| | Single-donor platelets reduce the risk of septic platelet transfusion reactions | Q49166133 |
| | Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. | Q52247763 |
| | The second century of ABO: and now for something completely different. | Q53535347 |
| | Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. | Q53784097 |
| | Transfusion-transmitted bacterial infection in the United States, 1998 through 2000 | Q64128628 |
| | Platelet prophylaxis in acute non-lymphoblastic leukaemia | Q66697566 |
| | Antibodies to plasma proteins: an association with platelet transfusion refractoriness | Q68059093 |
| | Platelet transfusion therapy | Q68496759 |
| | Transfusion of ABO-mismatched platelets leads to early platelet refractoriness | Q68534410 |
| | Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation | Q70135390 |
| | The role of ABO matching in platelet transfusion | Q70578075 |
| | Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage | Q71015036 |
| | Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays | Q71028534 |
| | Invasive line placement in critically ill patients: do hemostatic defects matter? | Q71572297 |
| | Interaction of platelet fc and complement receptors with circulating immune complexes involving the AB0 system | Q71870429 |
| P433 | issue | 3 | |
| P921 | main subject | platelet transfusion | Q23925170 |
| P304 | page(s) | 149-165 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Blood Reviews | Q15724415 |
| P1476 | title | Optimizing platelet transfusion therapy | |
| P478 | volume | 18 | |